Clinical translation of angiogenesis inhibitors - PubMed (original) (raw)
Review
doi: 10.1038/nrc905.
Affiliations
- PMID: 12360276
- DOI: 10.1038/nrc905
Review
Clinical translation of angiogenesis inhibitors
Robert Kerbel et al. Nat Rev Cancer. 2002 Oct.
Abstract
Angiogenesis inhibitors are a new class of drugs, for which the general rules involving conventional chemotherapy might not apply. The successful translation of angiogenesis inhibitors to clinical application depends partly on the transfer of expertise from scientists who are familiar with the biology of angiogenesis to clinicians. What are the most common questions that clinicians ask as they begin to test angiogenesis inhibitors in cancer clinical trials?
Similar articles
- Angiogenesis inhibitors in cancer therapy.
Dredge K, Dalgleish AG, Marriott JB. Dredge K, et al. Curr Opin Investig Drugs. 2003 Jun;4(6):667-74. Curr Opin Investig Drugs. 2003. PMID: 12901224 Review. - Cancer research. Obstacle for promising cancer therapy.
Marx J. Marx J. Science. 2002 Feb 22;295(5559):1444. doi: 10.1126/science.295.5559.1444a. Science. 2002. PMID: 11859164 No abstract available. - Clinical trials referral resource. Current clinical trials of thalidomide.
Streicher HZ, Vereshchagina LA, Schoenfeldt M. Streicher HZ, et al. Oncology (Williston Park). 2003 Mar;17(3):369-71, 374-5, 379-80. Oncology (Williston Park). 2003. PMID: 12661268 No abstract available. - [Bone marrow angiogenesis in multiple myeloma: new insights into the pathogenesis, and development of a new therapeutic approach].
Hattori Y, Kakimoto T. Hattori Y, et al. Rinsho Ketsueki. 2000 May;41(5):426-9. Rinsho Ketsueki. 2000. PMID: 10879105 Review. Japanese. No abstract available. - [The clinical perspective of angiogenesis inhibitors].
Radema SA, Witteveen PO, Gebbink MB, Voest EE. Radema SA, et al. Ned Tijdschr Geneeskd. 2003 Aug 30;147(35):1675-80. Ned Tijdschr Geneeskd. 2003. PMID: 14513538 Review. Dutch.
Cited by
- Comprehensive overview of the efficacy and safety of sorafenib in advanced or metastatic renal cell carcinoma after a first tyrosine kinase inhibitor.
Afonso FJ, Anido U, Fernández-Calvo O, Vázquez-Estévez S, León L, Lázaro M, Ramos M, Antón-Aparicio L. Afonso FJ, et al. Clin Transl Oncol. 2013 Jun;15(6):425-33. doi: 10.1007/s12094-012-0985-x. Epub 2013 Feb 12. Clin Transl Oncol. 2013. PMID: 23401018 Review. - Angiogenesis as a hallmark of solid tumors - clinical perspectives.
Majidpoor J, Mortezaee K. Majidpoor J, et al. Cell Oncol (Dordr). 2021 Aug;44(4):715-737. doi: 10.1007/s13402-021-00602-3. Epub 2021 Apr 9. Cell Oncol (Dordr). 2021. PMID: 33835425 Review. - Discovery and Optimization of N-Substituted 2-(4-pyridinyl)thiazole carboxamides against Tumor Growth through Regulating Angiogenesis Signaling Pathways.
Zhou W, Tang W, Sun Z, Li Y, Dong Y, Pei H, Peng Y, Wang J, Shao T, Jiang Z, Yi Z, Chen Y. Zhou W, et al. Sci Rep. 2016 Sep 16;6:33434. doi: 10.1038/srep33434. Sci Rep. 2016. PMID: 27633259 Free PMC article. - Long non-coding RNA taurine upregulated 1 enhances tumor-induced angiogenesis through inhibiting microRNA-299 in human glioblastoma.
Cai H, Liu X, Zheng J, Xue Y, Ma J, Li Z, Xi Z, Li Z, Bao M, Liu Y. Cai H, et al. Oncogene. 2017 Jan 19;36(3):318-331. doi: 10.1038/onc.2016.212. Epub 2016 Jun 27. Oncogene. 2017. PMID: 27345398 - Increased production of soluble vascular endothelial growth factors receptor-1 in CHO-cell line by using new combination of chitosan-protein lipid nanoparticles.
Farnia P, Ghanavi J, Bahrami A, Bandehpour M, Kazemi B, Velayati AA. Farnia P, et al. Int J Clin Exp Med. 2015 Jan 15;8(1):1526-33. eCollection 2015. Int J Clin Exp Med. 2015. PMID: 25785168 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources